Principal Financial Group Inc. Buys 86,764 Shares of SOPHiA GENETICS SA (NASDAQ:SOPH)

Principal Financial Group Inc. grew its position in shares of SOPHiA GENETICS SA (NASDAQ:SOPH) by 6.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,455,142 shares of the company’s stock after buying an additional 86,764 shares during the quarter. Principal Financial Group Inc. owned 2.23% of SOPHiA GENETICS worth $5,290,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Green Alpha Advisors LLC bought a new stake in SOPHiA GENETICS during the third quarter valued at approximately $79,000. Federated Hermes Inc. grew its position in shares of SOPHiA GENETICS by 57.5% during the 2nd quarter. Federated Hermes Inc. now owns 63,000 shares of the company’s stock valued at $289,000 after acquiring an additional 23,000 shares during the period. Finally, Banque Cantonale Vaudoise increased its stake in shares of SOPHiA GENETICS by 300.0% in the 2nd quarter. Banque Cantonale Vaudoise now owns 12,000 shares of the company’s stock worth $55,000 after purchasing an additional 9,000 shares in the last quarter. 31.59% of the stock is currently owned by hedge funds and other institutional investors.

SOPHiA GENETICS Stock Performance

Shares of NASDAQ SOPH opened at $3.07 on Thursday. The firm’s fifty day moving average is $3.38 and its two-hundred day moving average is $3.80. SOPHiA GENETICS SA has a 52-week low of $2.70 and a 52-week high of $7.37. The company has a market cap of $200.70 million, a P/E ratio of -2.82 and a beta of 0.99. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.59 and a current ratio of 3.80.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.04). The firm had revenue of $15.85 million for the quarter, compared to analysts’ expectations of $15.90 million. SOPHiA GENETICS had a negative net margin of 110.71% and a negative return on equity of 55.06%. During the same quarter in the prior year, the business earned ($0.21) EPS. As a group, analysts anticipate that SOPHiA GENETICS SA will post -0.98 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Craig Hallum began coverage on shares of SOPHiA GENETICS in a research note on Wednesday, December 18th. They set a “buy” rating and a $11.00 target price on the stock. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, SOPHiA GENETICS has an average rating of “Moderate Buy” and an average price target of $7.40.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.